Oxidative stress in renal transplant patients who develop cardiovascular disease

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 11, Issue 3, 2006, Pages 203-210

  El Ghar, Suzan M G A ^a   Qureshi, Mabood ^a   Shoker, Ahmed ^b   Prasad, Kailash ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Cardiovascular disease; Malondialdehyde; Oxidative stress

Indexed keywords

GLUTATHIONE; HOMOCYSTEINE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE;

ADULT; AGE; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; KIDNEY GRAFT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; CANADA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ERYTHROCYTES; FEMALE; GLUTATHIONE; HOMOCYSTEINE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; POSTOPERATIVE COMPLICATIONS; REACTIVE OXYGEN SPECIES;

EID: 33749571123     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248406293254     Document Type: Article

References (61)

1. Dimeny EM. Cardiovascular disease after renal transplantation. Kidney Int. 2002;80(suppl):S78-S84.
2. Arend SM, Mallat MJ, Westendorp RJ, et al. Patient survival after renal transplantation: more than 25 years follow up. Nephrol Dial Transplant. 1997;12:1672-1679.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S16-S23.
4. Van Dijk PC, Jager KJ, de Charro F, et al. Renal replacement therapy in Europe: the result of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant. 2001;16:1120-1129.
5. Lindholm A, Albrechtsen D, Frodin L, et al. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. 1995;60:451-457.
6. Aakhus S, Dahl K, Wideroe TE. Cardiovascular morbidity and risk Factors in renal transplant patients. Nephrol Dial Transplant. 1999;14:648-654.
7. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol. 1998;30:777-788.
8. Beto JA, Bansal VK. Interventions for other risk factors: tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis. 1998;32(suppl 3):S172-S183.
9. Kasiske BL, Klinger D. Cigarette smoking in renal transplant recipients. J Am Soc Nephrol. 2000;11:753-759.
10. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J. 1993;125:958-973.
11. Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther. 2003;8:61-69.
12. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation. 1999;99:1355-1362.
13. Prasad K, Mantha SV, Muir AD, Westcott ND. Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha-linolenic acid. Atherosclerosis. 1998;136:367-375.
14. Prasad K. Pathophysiology of atherosclerosis. In: Chang IB, Olsen ER, Prasad K, Sumpio BE, eds. Textbook of Angiology. New York, NY: Springer Verlag; 2000:85-105.
15. Prasad K. Secoisolariciresinol diglucoside from flaxseed delays the development of type-2 diabetes in Zucker rat. J Lab Clin Med. 2001;138:32-39.
16. Armstrong AM, Chestnutt JE, Gormley MJ, Young IS. The effect of dietary treatment on lipid peroxidation and antioxidant status in newly diagnosed non-insulin dependent diabetes. Free Radic Biol Med. 1996;21:719-726.
17. Kalra J, Chaudhary AK, Prasad K. Increased production of oxygen free radicals in cigarette smokers. Int J Exp Pathol. 1991;72:1-7.
18. Heinecke JW, Rosen H, Suzuki LA, et al. The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem. 1987;262:10098-10103.
19. Prasad K. Homocysteine, a risk factor for cardiovascular disease. Int J Angiol. 1999;8:76-86.
20. Prasad K. Hypercholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis. 2005;179:269-275.
21. Kapoor R, Prasad K. Role of oxyradicals in cardiovascular depression and cellular injury in hemorrhagic shock and reinfusion: effect of SOD and catalase. Circ Shock. 1994;43:79-94.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
23. Shipchandler MT, Moore EG. Rapid, fully automated measurement of plasma homocysteine with the Abbott IMx analyzer. Clin Chem. 1995;41:991-994.
24. Brigelius R, Muckel C, Akerboom T, et al. Identification and quantitation of glutathione in hepatic protein mixed disulfides and its relationship to glutathione disulfide. Biochem Pharmacol. 1983;32:2529-2534.
25. Perez Fernandez R, Martin Mateo MC, De Vega L, et al. Antioxidant enzyme determination and a study of lipid peroxidation in renal transplantation. Ren Fail. 2002;24:353-359.
26. Dasgupta A, Powell D, Saldana S, et al. Elevated lipid peroxidation products and depleted transferrin levels in the plasma of kidney transplant recipients. Life Sci. 1990;46:67-72.
27. Aukrust P, Berge RK, Muller F, et al. Elevated plasma levels of reduced homocysteine in common variable immunodeficiency: a marker of enhanced oxidative stress. Eur J Clin Invest. 1997;27:723-730.
28. Hribova P, Kotsch K, Brabcova I, et al. Cytokines and chemokine gene expression in human kidney transplantation. Transplant Proc. 2005;37:760-763.
29. Cueto-Manzano AM, Morales-Buenrostro LE, Gonzalez-Espinoza L, et al. Markers of inflammation before and after renal transplantation. Transplantation. 2005;80:47-51.
30. Coffman TM, Schwertschlag W, Yarger W, et al. Lipid mediators in acute renal allograft rejection. Transplant Proc. 1986;18:94-97.
31. Butterly BW, Spurney RF, Ruiz P, et al. Role of platelet activating factor in kidney transplant rejection in the rat. Kidney Int. 1995;48:337-343.
32. Kirschfink M, Wienert T, A Prado EB, Pomer S. The effect of the complement system on the acute reversible rejection of kidney transplants. Immun Infekt. 1995;23:55-56.
33. Loss M, Vangerow B, Schmidtko J, et al. Acute vascular rejection is associated with systemic complement activation in pig-to-primate kidney xenograft model. Xenotransplantation. 2000;7:186-196.
34. Emingil G, Coker I, Atilla G, Huseyinov A. Levels of leukotriene B4 and platelet activating factor in gingival crevicular fluid in renal transplant patients receiving cyclosporine A. J Periodontol. 2000;71:50-57.
35. Sezer S, Akcay A, Ozdemir FN, et al. Post-transplant C - reactive protein monitoring can predict chronic allograft nephropathy. Clin Transplant. 2004;18:722-725.
36. Perez RV, Brown DJ, Katznelson SA, et al. Pre-transplant systemic inflammation and acute rejection after renal transplantation. Transplantation. 2000;69:869-874.
37. Fink JC, Onuigbo MA, Blahut SA, et al. Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. Am J Kidney Dis. 2002;39:1096-1101.
38. Sumimoto H, Takeshige K, Minakami S. Superoxide production of human polymorphonuclear leukocytes stimulated by leukotriene B4. Biochim Biophys Acta. 1984;803:271-277.
39. Shaw JO, Pinckard RN, Ferrigni KS, et al. Activation of human neutrophils with 1-0-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet-activating factor). J Immunol. 1981;127:1250-1255.
40. Braquet P, Hosford D, Braquet M, et al. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88:88-100.
41. Paubert-Braquet M, Longchampt MO, Koltz P, Guilbaud J. Tumor necrosis factor (TNF) primes human neutrophils (PMN) platelet-activating (PAF)-induced superoxide generation: Consequences in promoting PMN-mediated endothelial cell (EC) damages. Prostaglandins. 1988;35:803.
42. Webster RO, Hong SR, Johnston RB Jr, Henson PM. Biological effects of the human complement fragments C5a and C5a des Arg on neutrophil function. Immunopharmacology. 1980;2:201-219.
43. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther. 2004;9:203-209.
44. Sobki SH, Khan SA, Al Mofawez TA, et al. Homocysteine in renal transplant recipients: association with transplant duration and renal function. Ren Fail. 2004;26:265-271.
45. Marcucci R, Zanazzi M, Bertoni E, et al. Homocysteine-lowing therapy and carotid intima-media thickness in renal transplant recipients. Transplant Proc. 2005;37:2491-2492.
46. Manrique J, Diaz A, Gavira JJ, et al. Preliminary results of the effect of treatment of hyperhomocysteinemia and its relationship with inflammation, coagulation status, and endothelial function after renal transplant. Transplant Proc. 2005;37:3782-3784.
47. Diaz JM, Sainz Z, Gich I, et al. Facts involved in base-line hyperhomocysteinemia in renal transplantation. Transplant Proc. 2005;37:3799-3801.
48. Arnadottir M, Hultberg B, Wahlberg J, et al. Serum total homocysteine concentration before and after renal transplantation. Kidney Int. 1998;54:1380-1384.
49. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relationship of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
50. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1998;98:204-210.
51. Evans RW, Shaten BJ, Hempel JD, et al. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol. 1997;17:1947-1953.
52. Bostom AG, Cupples A, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA. 1996;276:544-548.
53. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57:1727-1735.
54. Suliman ME, Lindholm B, Barany P, Bergstrom J. Hyperhomocysteinemia in chronic renal failure patients: relation to nutritional status and cardiovascular disease. Clin Chem Lab Med. 2001;39:734-738.
55. Bostom AG: Homocysteine: "expensive creatinine" or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients? J Am Soc Nephrol. 2000;11:149-151.
56. Hagen W, Fodinger M, Heinz G, et al. Effect of MTHFR genotypes and hyperhomocysteinemia on patients and graft survival in kidney transplant recipients. Kidney Int. 2001;Suppl 78:8253-8257.
57. Klemm A, Voigt C, Friedrich M, et al. Determination of erythrocyte antioxidant capacity in hemodialysis patients using electron paramagnetic resonance Nephrol Dial Transplant. 2001;16:2166-2171.
58. El-Rashidy FH, Al-Turk WA, Stohs SJ. Glutathione, glutathione reductase and glutathione S-transferase activities in erythrocytes and lymphocytes in chronic renal disease. Res Commun Chem Pathol Pharmacol. 1984;44:423-430.
59. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996;21:845-853.
60. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;19:53-61.
61. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538.